The FDA authorized an updated label for diabetes medicines containing pioglitazone, such as Takeda Pharmaceutical's Actos, that includes data on increased risk of bladder cancer in patients treated for more than one year. Also, clinicians are advised against giving such drugs to patients with active bladder cancer and should be cautious about treating those with a history of the cancer.

Related Summaries